Cardiovascular Market Research Reports & Industry Analysis
Variations in heart size and position within the chest may be related to age, body size, shape, weight, or pathologic conditions of the heart and other nearby structures.
There has been considerable study into the role of inflammation in heart disease. Researchers have found the first direct evidence that reducing inflammation in coronary arteries decreases the risk of heart attacks as much as reducing cholesterol levels. This finding offers a new approach to preventing heart disease. Two studies showed that inflammation of the arteries can be reduced by more aggressive use of statins. New drugs that target inflammation that are measured by a marker called Creactive rotein (CRP) could have a large impact on cardiovascular health as well as a large financial gain for companies developing these products.
Cardiovascular Industry Research & Market Reports
-
Isosorbide - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
... forecast period 2024-2030. North American market for Isosorbide was valued at $ 30.30 million in 2023 and will reach $ 68.92 million by 2030, at a CAGR of 13.55% during the forecast period of 2024 ... Read More
-
Cardiovascular and Soft Tissue Repair Patches
... reach US$8.3 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. ePTFE Material, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach ... Read More
-
Cardiology IT Workflow Solutions
... 2030, growing at a CAGR of 8.0% over the analysis period 2024-2030. Cloud Deployment, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$1.1 Billion by the ... Read More
-
Perfusion Systems
... CAGR of 4.4% over the analysis period 2024-2030. Cardiopulmonary Perfusion Systems, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$671.0 Million by the end of the ... Read More
-
Cardiovascular Repair and Reconstruction Devices
... Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Cardiovascular Grafts, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$4.3 Billion ... Read More
-
Congestive Heart Failure (CHF) Treatment Devices
... reach US$37.9 Billion by 2030, growing at a CAGR of 7.1% over the analysis period 2024-2030. Implantable Cardioverter Defibrillators, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and ... Read More
-
Stroke Management
... CAGR of 5.3% over the analysis period 2024-2030. Diagnostics Type, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$35.9 Billion by the end of the analysis ... Read More
-
Cardiovascular Disease Monitoring and Diagnostic Devices
... reach US$3.6 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. ECG Systems, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach ... Read More
-
Angina Pectoris Drugs
... at a CAGR of 4.5% over the analysis period 2024-2030. Beta Blockers, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$9.6 Billion by the end of ... Read More
-
Cardiovascular Ultrasound Systems
... at a CAGR of 5.1% over the analysis period 2024-2030. Stress Echocardiogram Test, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$1.0 Billion by the end ... Read More
-
Heart Failure Drugs
... at a CAGR of 12.4% over the analysis period 2024-2030. The U.S. Market is Estimated at US$2.4 Billion While China is Forecast to Grow at 16.3% CAGR The Heart Failure Drugs market in the U.S. ... Read More
-
C-Reactive Protein Testing
... at a CAGR of 1.7% over the analysis period 2024-2030. Cardiovascular Diseases, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$1.0 Billion by the end of ... Read More
-
Critical Care Therapeutics
... at a CAGR of 5.7% over the analysis period 2024-2030. Albumin, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$3.7 Billion by the end of the ... Read More
-
Embolotherapy
... 7.7% over the analysis period 2024-2030. Embolic Agents, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$6.7 Billion by the end of the analysis period. Growth ... Read More
-
Patient Monitoring Devices
... at a CAGR of 7.5% over the analysis period 2024-2030. Blood Glucose Monitoring Device, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$23.2 Billion by the ... Read More
-
Acute Heart Failure (AHF) Therapeutics
... Billion by 2030, growing at a CAGR of 21.0% over the analysis period 2024-2030. Cardiac Glycosides, one of the segments analyzed in the report, is expected to record a 21.5% CAGR and reach US$762.4 Million ... Read More
-
Cholesterol Testing
... CAGR of 4.4% over the analysis period 2024-2030. Diagnostic Centers End-Use, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$11.6 Billion by the end of the ... Read More
-
Acute Coronary Syndrome
... at a CAGR of 10.5% over the analysis period 2024-2030. The U.S. Market is Estimated at US$2.6 Billion While China is Forecast to Grow at 16.2% CAGR The Acute Coronary Syndrome market in the U.S. ... Read More
-
Acute Ischemic Stroke Diagnosis and Treatment
... reach US$3.1 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Computed Tomography Diagnosis, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and ... Read More
-
Dilated Cardiomyopathy Therapeutics
... at a CAGR of 4.3% over the analysis period 2024-2030. Angiotensin II Receptor Blockers (ARBs), one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$258.2 Million by ... Read More
-
Anticoagulants
... 9.2% over the analysis period 2024-2030. NOACs, one of the segments analyzed in the report, is expected to record a 10.8% CAGR and reach US$33.4 Billion by the end of the analysis period. Growth in ... Read More
-
Statins
... 1.8% over the analysis period 2024-2030. Synthetic Statins, one of the segments analyzed in the report, is expected to record a 2.0% CAGR and reach US$12.2 Billion by the end of the analysis period. Growth ... Read More
-
Cardiovascular Catheters
... CAGR of 6.6% over the analysis period 2024-2030. Cardiovascular Therapeutic Catheters, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$25.4 Billion by the end of the ... Read More
-
Enzyme Inhibitor Global Market Report 2025
... is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond. Reasons to Purchase Gain a truly global perspective with the ... Read More
-
Stroke - Global Clinical Trials Review, 2025
... the clinical trials on Stroke. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 ... Read More
Research Assistance
